Plus Therapeutics, Inc.
PSTV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | 0.01 | 0.03 |
| FCF Yield | -140.13% | -236.71% | -160.46% | -82.24% |
| EV / EBITDA | -1.30 | -0.09 | 0.22 | -0.11 |
| Quality | ||||
| ROIC | 263.26% | -280.03% | -142.40% | -69.63% |
| Gross Margin | 85.37% | -97.23% | -217.86% | 0.00% |
| Cash Conversion Ratio | 0.81 | 0.97 | 0.64 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | 196.25% | – | -9.58% | -100.00% |
| Free Cash Flow Growth | 17.76% | 3.49% | -29.33% | -16.77% |
| Safety | ||||
| Net Debt / EBITDA | -0.39 | 0.34 | 0.66 | 0.95 |
| Interest Coverage | -3.95 | -33.72 | -27.72 | -13.40 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,022.91 | -179.22 | -4,287.72 | -14,439.62 |